JAKARTA — PT Fonko International Pharmaceuticals has recorded several key milestones in the development of oncology drug manufacturing in Indonesia. These achievements include securing European Union Good Manufacturing Practice (EU GMP) certification in 2025, developing a range of “first copy” products for cancer therapy, and obtaining halal certification for its entire oncology product line. This progress builds on Fonko’s ongoing commitment to expanding domestic production

TANGERANG — PT Ferron Par Pharmaceuticals, a member of Dexa Group, has won the 2026 Indonesia Halal Industry Award (IHYA) from the Ministry of Industry of the Republic of Indonesia in the Large Industrial Enterprise Category, Subcategory of Best Pharmaceuticals and Traditional Medicines. This award recognizes Dexa Group’s consistency in implementing the Halal Product Assurance System (SJPH). To date, all of Dexa Group’s production facilities and products have been certified h

JAKARTA — Indonesia recorded 474,083 new cases and 283,299 deaths due to cancer, according to 2024 Global Cancer Observatory (GLOBOCAN) data. This situation underscores the critical role of Ferron Par Pharmaceuticals in expanding its support for cancer patients—from delivering access to medications to strengthening chemotherapy support facilities through the provision of Cytostatic Drug Preparation Units (TPO Sitostatika) in more than 10 hospitals across Indonesia, including

JAKARTA — Amid a series of natural disasters impacting various regions across Indonesia throughout 2026, Dexa Group, through its Corporate Social Initiative Dharma Dexa, continues to strengthen its commitment to safeguarding health and inspiring hope for affected communities. This step marks part of Dexa Group’s 57th-anniversary spirit to extend meaningful care tailored to the specific needs of each region. From medical supplies and shelter to preventive health protection and

JAKARTA – For more than three decades, Dexa Group has consistently contributed to providing quality medicines for the Indonesian people through Obat Generik Berlogo/OGB (unbranded generics) Dexa. Today, OGB Dexa produces more than 2 billion units annually with over 140 SKUs to support the National Health Insurance (JKN) program. This contribution to ensuring the availability of quality and affordable medicines has been ongoing since production began in 1991. In 1991, Dexa Med

JAKARTA — Globally, the condition long known as polycystic ovary syndrome (PCOS) is estimated to affect more than 170 million women, or approximately one in eight women of reproductive age. The vast prevalence and far-reaching impact of this condition led to a global consensus published in The Lancet in 2026, proposing a name change from PCOS to polyendocrine metabolic ovarian syndrome (PMOS). This new nomenclature is considered to better reflect the multisystem nature of the

JAKARTA – For 27 years, Stimuno has been an integral part of the health journey for Indonesian families. Since its debut in 1999, this natural immunomodulator medication has accompanied families across generations, helping maintain strong immune systems so the body is better prepared to face various health challenges. Stimuno’s long journey is a testament to its consistency in delivering products tailored to family needs, earning lasting trust through uncompromised quality st

JAKARTA — The rapid growth of Artificial Intelligence (AI) and digital technology is driving significant shifts across the healthcare ecosystem—from drug discovery and clinical practice to doctor-patient dynamics. These transformations formed the core discussion at the 2026 Dexa Periodic Scientific Meeting (PERIXA), which carried the theme “Navigating the Bio-Digital Era to Heal Diverse Populations” in Jakarta on Sunday, September 6, 2026. Natalia Maria, Marketing Director of

SOUTH TANGERANG – A healthy lifestyle is more than a passing trend; it is an essential part of maintaining long-term quality of life. This message was at the heart of the Indonesia Wellness Festival (Wellfest) 2026, themed “The New Paradigm of Sustainable Living,” held from September 4–6, 2026, at Bintaro Jaya Xchange Mall, South Tangerang. In line with this spirit, Dexa Group participated by presenting various activities encouraging the public to pay greater attention to the

JAKARTA – Dexa Group is strengthening Indonesia’s national pharmaceutical ecosystem by empowering 413 farmers across 34 districts in 11 provinces to supply raw materials for medicines derived from Indonesia’s biodiversity. The Green Pharmacy initiative, one of the implementations of Dexa Group’s Right to Win strategy, has once again earned the company recognition through the detikcom Green Economy Award, in the Community Economy Appreciation category. The award recognizes Dex